Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;203(2):253-60.
doi: 10.2214/AJR.14.12554.

Molecular targeted α-particle therapy for oncologic applications

Thaddeus J Wadas  1 , Darpan N Pandya, Kiran Kumar Solingapuram Sai, Akiva Mintz
Affiliations
Review

Molecular targeted α-particle therapy for oncologic applications

Thaddeus J Wadas et al. AJR Am J Roentgenol. 2014 Aug.

Abstract

Objective: A significant challenge facing traditional cancer therapies is their propensity to significantly harm normal tissue. The recent clinical success of targeting therapies by attaching them to antibodies that are specific to tumor-restricted biomarkers marks a new era of cancer treatments.

Conclusion: In this article, we highlight the recent developments in α-particle therapy that have enabled investigators to exploit this highly potent form of therapy by targeting tumor-restricted molecular biomarkers.

Keywords: 213Bi; 223Ra; 225Ac; molecular radiotherapy; nuclear medicine; radioimmunotherapy; α-particle therapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Illustration of monoclonal antibody conjugated to chemotherapeutic agent. Potentially toxic chemotherapeutic agents can be targeted to tumor-restricted biomarkers by attaching them to specific delivery systems, such as antibodies, that bring them directly to tumor cells and spare normal tissue from their deleterious effects. (Drawing by Mintz A)
Fig. 2
Fig. 2
Images show comparison of clearance of radiolabeled antibody versus peptide. A, Anterior whole-body planar scintigraphy of a 72-year-old man with suspected recurrent prostate cancer obtained 3 days after administration of 5.1 mCi (188.7 MBq) of 111In capromab pendetide (ProstaScint, Cytogen) antibody shows significant residual activity in blood pool (heart and great vessels) even 3 days after administration. B, Whole-body anterior (left) and posterior (right) planar images of a 49-year-old woman with a suspected gastrinoma obtained 4 hours after administration of 6.0 mCi (222.0 MBq) of 111In pentetreotide show little visible activity seen in blood pool (in regions of heart and great vessels) only hours after administration, in contrast to what is seen with high-molecular-weight antibodies (A). Images also show significant renal uptake as well as clearance into bladder.
See this image and copyright information in PMC

References

    1. Wissing MD, van Leeuwen FW, van der Pluijm G, Gelderblom H. Radium-223 chloride: extending life in prostate cancer patients by treating bone metastases. Clin Cancer Res. 2013;19:5822–5827. - PubMed
    1. U.S. Food and Drug Administration. Food and Drug Administration website; [Accessed April 23, 2014]. FDA approves new treatment for late-stage breast cancer. www.fda.gov/newsevents/newsroom/pressannouncements/ucm340704.htm. Published February 22, 2013. Updated February 26, 2013.
    1. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies: not four letter words. Q J Nucl Med Mol Imaging. 2004;48:251–257. - PubMed
    1. NeutroSpec withdrawn from market. J Nucl Med. 2006;47:36N–41N. - PubMed
    1. Love C, Tronco GG, Palestro CJ. Imaging of infection and inflammation with 99mTc-Fanolesomab. Q J Nucl Med Mol Imaging. 2006;50:113–120. - PubMed

Publication types

MeSH terms